DOAC does not prevent cognitive decline in adults with AF an

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LDL-C Management Trends in ASCVD Patients
LDL-C Management Trends in ASCVD Patients
Heart Matters
LDL-C Management Trends in ASCVD Patients
- Keith C. Ferdinand, MD
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Heart Matters
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
Heart Matters
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
Heart Matters
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil

DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke